(AOF) – Innate Pharma (+4% to 0.028 euros) announces today that several abstracts, including an oral presentation, have been selected for the 65th annual meeting of the ASH (American Society of Hematology) 2023, organized from 9 to December 13, 2023 in San Diego (United States). The positive results of the Tellomak Phase 2 trial evaluating its product lacutamab in heavily pretreated patients with relapsed or refractory Sézary syndrome were selected for oral presentation.
Preliminary clinical data from the Phase 1b trial with lacutamab monotherapy and preclinical combinability data in patients with peripheral T-cell lymphoma will be presented in a poster. Also planned is a presentation with SAR443579 / IPH6101, the most advanced drug candidate on the Anket platform under development by Innate partner Sanofi, which has demonstrated clinical remissions.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
